Molecular And Spatial Characterization Of Drug Resistance In Human Ovarian Cancer

Grant number: 1161198 | Funding period: 2019 - 2021



Ovarian cancer is the most deadly gynecologic cancer in Western women. Although initially responsive to chemotherapy, drug resistance commonly evolves in a matter of months. We previously documented novel mechanisms of drug resistance in the most common form of ovarian cancer and in this study we will map their distribution within patients. We will also investigate mechanisms of resistance to a new important class of anti-cancer drugs in ovarian cancer, the PARP inhibitors.